Notice of Allowability	Application No.	Applicant(s)
	08/786,988	LITTLE ET AL.
	Examiner	Art Unit
	Yelena G. Gakh, Ph.D.	1743
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>amendment filed on 01/17/07 and Declaration filed on 12/21/06.</u>		
2. A The allowed claim(s) is/are 147-169,172,173,175-178 and 180-184.		
 3.		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1:84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. Notice of References Cited (PTO-892)	5. Notice of Informal Pa	atent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary ((PTO-413),
3. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 02/15/07	Paper No./Mail Date 7. ⊠ Examiner's Amendm	ent/Comment
 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material 	8. 🛭 Examiner's Statemen	nt of Reasons for Allowance
of biological Material	9.	
·		

Application/Control Number: 08/786,988

Art Unit: 1743

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Bruce Grant on 03/01/07.

The application has been amended as follows:

In claim 147 at the end of step (a), after "a substrate", insert -- by an automated dispenser --.

In claim 149, after "wherein the substrate" replace [comprises] with -- is selected from the group consisting of --.

In claims 150 and 154: replace [147] with -- 149 --.

In claims 151-153 and 155: replace [147] with -- 148 --.

In claims 157 and 158: replace [147] with -- 156 --.

In claim 160: replace [147] with -- 159 --.

In claim 165: replace [147] with -- 164 --.

Delete claims 170, 171, 174 and 179.

In claim 176: replace [174] with -- 175 --.

In claim 177: replace [175] with -- 176 --.

Claims 147-169, 172-173, 175-178 and 180-184 are allowed. The new numbering of claims is 1 through 34.

The following is an examiner's statement of reasons for allowance: the prior art does not teach or fairly suggest a process for preparing a substrate having an arrays of spots for MALDI by depositing a defined and controlled 0.2-20 nL solution of 3-hydroxypicolinic matrix that does not comprising an analyte, and evaporating the solvent. The application was also reconsidered in light of the Declaration under 37 CFR 1.132 by Thomas Becker filed on 12/21/06, which was persuasive.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yelena G. Gakh, Ph.D. whose telephone number is (571) 272-1257. The examiner can normally be reached on 9:30 am - 6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jill A. Warden can be reached on (571) 272-1267. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

3/1/07

YELENA GAKH PRIMARY EXAMINER

lu Hale